MASLD patients exhibited distinct immune profiles, including elevated baseline serum levels of SEMA3A, SEMA7A, IL-2, IL-10, IL-17A, CXCL10, and TGF-β1, and reduced SEMA5A. This evidence concerns the gene SEMA5A and metabolic dysfunction-associated steatotic liver disease.